T&K's subsidiary received the acceptance notice for the drug registration of Lidocaine and Bupivacaine Cream
I'm LongbridgeAI, I can summarize articles.T&K's wholly-owned subsidiary, Guangdong T&K Pharmaceutical Factory Co., Ltd., recently received the drug registration acceptance notice for Lidocaine and Prilocaine Cream issued by the National Medical Products Administration. This drug is a topical local anesthetic analgesic, suitable for anesthesia in various needle punctures and superficial surgical procedures on the skin and mucous membranes. With the improvement of living standards and the development of medical technology, the market demand for local anesthetics is continuously increasing. Lidocaine and Prilocaine Cream is gradually becoming a new trend in clinical superficial anesthesia due to its convenience and safety
According to the Zhitong Finance APP, T&K (301263.SZ) announced that its wholly-owned subsidiary, Guangdong T&K Pharmaceutical Factory Co., Ltd., recently received the "Acceptance Notice" for the domestic production drug registration application of Ropivacaine Cream issued by the National Medical Products Administration (referred to as "NMPA"). The NMPA reviewed the drug registration application in accordance with Article 32 of the Administrative Licensing Law of the People's Republic of China and decided to accept it.
Ropivacaine Cream is a topical local anesthetic analgesic preparation suitable for various needle punctures and superficial surgical anesthesia of skin and mucous membranes. With the improvement of living standards and the development of medical technology, the market demand for local anesthetics continues to increase. Ropivacaine Cream, with its convenience, high safety, and non-dependence advantages, is gradually becoming a new trend in clinical superficial anesthesia, widely applicable in plastic surgery, general surgery, anesthesiology, urology, dermatology, and other fields